A clinical trial of the injected rat nerve growth factor (mNGF) in the treatment of Spinocerebellar ataxia

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001954

Enrollment

Unknown

Registered

2011-07-15

Start date

2011-08-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinocerebellar ataxia

Interventions

1:rat nerve growth factor

Eligibility

Sex/Gender

All

Age

7 Years to 74 Years

Inclusion criteria

Inclusion criteria: 1. To be diagnosed as Spinocerebellar ataxia; 2. Both male and female; 3. Aged 6~75 years; 4. Willing to attend the trial.

Exclusion criteria

Exclusion criteria: (1) Attended other trials of developing new drugs in recent three months; (2) Used other neurotrophic drugs, such as Cerebrolysin, ATP, Neurotropin, Ganglioside, etc.; (3) Patients have history of allergies for bio products; (4) Patients with mental disorders, dementia, speech impairment who unable to complete the protocol; (5) Patients have history of sever heart diseases, such as AMI, unstable agina, chronic heart failure III~IV grade, serious arrhythmias, include ventricular tachycardia, ventricular atrial fibrillation, and COPD; (6) Any reason cannot complete the ICARS score instrament and SARA scores instrament; (7) To be considered unable to attend the trial by the trialist.

Design outcomes

Primary

Measure	Time frame
ICARS scores;SARA scores;ADL score;	—

Countries

China

Contacts

Public ContactXu Yiming

xuyuming@zzu.edu.cn+86 0371 66913290

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026